ClinicalTrials.Veeva

Menu

TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

C

CTTQ

Status and phase

Enrolling
Phase 1

Conditions

Other Solid Tumors
Osteosarcoma

Treatments

Drug: 1800mg of TQB2928 injection+Anlotinib
Drug: 1200mg of TQB2928 injection+Anlotinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT06438783
TQB2928-ALTN-Ib-01

Details and patient eligibility

About

This is a multicenter, open-label, multi-cohort Phase Ib trial to evaluate the efficacy and safety of TQB2928 injection combined with anlotinib hydrochloride capsule in patients with relapsed/metastatic osteosarcoma and other relapsed/metastatic solid tumors.

Enrollment

43 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Pathological diagnosis of high-grade osteosarcoma(cohort I),dedifferentiated liposarcoma or polytypic liposarcoma(cohort II),unsuitable for local treatment;

  • The requirements for front-line treatment received by subjects are as follows:

    1. Subjects with osteosarcoma have failed at least first-line chemotherapy and are not suitable for re-receiving first-line chemotherapy ,or progression within 6 months of the end of first-line therapy;
    2. Subjects with dedifferentiated liposarcoma or polytype liposarcoma who have received at least first-line chemotherapy failure for recurrent/metastatic sites or relapse during postoperative adjuvant chemotherapy or within 6 months after treatment(considered first-line treatment failure).

Exclusion criteria

  • History of hemolytic anemia from any cause (including Evans syndrome) within 3 months prior to first dosing;
  • Subjects with osteosarcoma or dedifferentiated liposarcoma/polytype liposarcoma who have previously used antiangiogenic tyrosine kinase inhibitors (TKI) or bevacizumab or its biosimilar, such as anlotinib, apatinib, lenvatinib, sorafenib, sunitinib, regorafenib, fruquintinib;
  • Previous antibody or fusion protein or small molecule drug targeting CD47 or Signal-regulatory protein α (SIRRP-α).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

43 participants in 2 patient groups

1200mg of TQB2928 injection +Anlotinib
Experimental group
Description:
21 days as a treatment cycle.
Treatment:
Drug: 1200mg of TQB2928 injection+Anlotinib
1800mg of TQB2928 injection+Anlotinib
Experimental group
Description:
21 days as a treatment cycle.
Treatment:
Drug: 1800mg of TQB2928 injection+Anlotinib

Trial contacts and locations

5

Loading...

Central trial contact

Lu Xie, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems